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Clinicians are always faced with a decision when confronted with a febrile patient; they
must decide between what is an infectious condition and what is not, and between what
merits hospital observation, what requires empirical antibiotic treatment and what needs
outpatient follow-up. In this respect, judgement based on medical history and physical
examination outweigh the predictive value of various laboratory markers of infection, as
the latter generally reﬂect a nonspeciﬁc reaction of the host to widely different infectious
and inﬂammatory stimuli. In the evaluation of speciﬁc subgroups of patients, e.g. those in
the intensive care unit, laboratory tests should also preferably form a continuum with
medical history and physical examination, aimed at clarifying host condition, the setting
and the source of a possible infection.
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When confronted with a febrile patient the clin-
ician determines by medical history and a thor-
ough physical examination whether the signs and
symptoms are suggestive of infection. For some
guidance, he may rely on laboratory tests such as
the erythrocyte sedimentation rate and white
blood cell count, differential and smear. A bacter-
ial infection may run an unpredictable course and
may rapidly give rise to potentially life-threaten-
ing complications, yet can be inﬂuenced favorably
by antibiotic therapy. Thus, in general practice,
clinicians make a decision ﬁrst as to whether the
infection is likely to be caused by bacteria or
viruses. This decision is based largely on the iden-
tiﬁcation of the probable source of infection, the
setting, and the characteristics of the host. The
micro-organisms involved can be largely inferred
from speciﬁc signs and symptoms reﬂecting the
primary source of the infection, e.g. pulmonary or
urinary tract infection, the setting of the infection
(community- or hospital-acquired), and whether it
occurs in a normal host or a in host compromised
by an underlying condition such as malignancy,
acquired immune deﬁciency syndrome, or use
of immunosuppressive medication. To obtain a
deﬁnite microbiological diagnosis, cultures of
the urine, sputum, discharge, or wounds are taken
and Gram-staining of these specimens can provide
a preliminary identiﬁcation of themicro-organism.
Blood cultures are taken in all patients hospita-
lized with infection. On the basis of their knowl-
edge and experience, clinicians learn to anticipate
speciﬁc infections in a host who lacks a certain
component of his defence that is essential in a
particular epidemiological setting. Understanding
the clinical presentation of the patient with an
infectious condition is essential for rapid diagnosis
and management of the disease.
This classical approach sufﬁces in most patients
with a febrile illness admitted to the acute-care
facility of a hospital. Studies indicate that over 85%
of patients with an acute febrile illness who are
referred by their primary-care physician to a hos-
pital, academic center, or community hospital
alike, are febrile due to an infection, mainly bac-
terial in origin [1–4]. In a population with such a
high prevalence of infection, laboratory tests
designed to evaluate the setting of infection (e.g.
granulocytopenia in a cancer patient receiving
chemotherapy), and to identify the source of infec-
tion by, for instance, urinalysis or chest X-ray, form
a logical continuum in conjunction with the med-
ical history and physical examination. Basically,
the latter increase the prevalence of disease in the
population selected for testing and so increase
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the predictive value of the test procedure. Rather
than assess whether infection is present, these
laboratory tests are performed to evaluate a partic-
ular setting or source of infection. In an elderly
man who presents with chills, fever, dyspnea and
pleurisy, a chest X-ray may reveal a lobar inﬁltrate
and Gram stain of sputum will show Gram-posi-
tive diplococci; laboratory tests that may help
differentiate between the presence or absence of
an infection are not needed, nor will their results
inﬂuence a clinician’s decision to treat the patient
for pneumococcal pneumonia.
However, in some patients, in particular those
hospitalized with a serious underlying condition
and requiring intensive care, clinical manifesta-
tions of infection are often subtle, atypical, or
nonexistent. Fever may be low or even absent,
yet the identiﬁcation of an infection or bacteremia
at an early stage of the disease is critical for a
favorable outcome. In this setting the clinician
cannot rely on classical signs and symptoms of
infection. Moreover, while in such patients an
infection may be a common cause of fever, many
underlying noninfectious inﬂammatory condi-
tions lead to a similar febrile response [5]. Some
recent reviews have outlined a systematic and
prudent approach to the management of a febrile
patient in an intensive care unit [6], and, clearly,
there is a need for sensitive and speciﬁc laboratory
markers of infection to help discern which patient
is truly infected.
The host reaction to inﬂammation can be clini-
cally manifested by the systemic inﬂammatory
response syndrome (SIRS) progressing — in
response to infection — to severe sepsis, septic
shock, adult respiratory distress syndrome
(ARDS) andmultiple organ dysfunction syndrome
[5]. These syndromes, designated to stratify
patients for severity of illness in clinical trials,
unify conditions that share signs of inﬂammation
and are executed through common mediators
including cytokines such as tumor necrosis fac-
tor-a (TNF-a), interleukin-1 (IL-1) and IL-6
(reviewed in [5]). In an infection, the chain of
events is triggered by live micro-organisms and
by bacterial components such as endotoxin, pep-
tidoglycan, lipoteichoic acid, lipoprotein and exo-
toxins [7,8]. Mediators of the local inﬂammatory
process at the site of infection are released into the
circulation and generate the systemic inﬂamma-
tory response characterized by clinical signs, such
as fever and an acute-phase protein response in the
blood. Alternatively, a local infectionmay progress
and extend directly into the systemic circulation,
giving rise to bacteremia. Unfortunately, clinical
syndromes such as SIRS and ARDS and the acute-
phase response are not triggered exclusively by
infection but can be caused by many noninfectious
conditions, e.g. in illness secondary to burns, pan-
creatitis and trauma, acute lung injury or following
cardiopulmonary bypass surgery [5,9–11]. In such
patients, to differentiate between an infectious and
noninfectious cause of the systemic inﬂammatory
response, bacteriological data are of limited help
as culture of tracheal aspirates, sputum, wounds,
catheter urine, etc., often yields a variety of colo-
nizing micro-organisms, and blood cultures take
time to grow. In the setting of the intensive care
unit (ICU), in which many manifestations of the
host response may be neither sensitive to nor
speciﬁc for infection, how can the clinician discern
which patient is truly infected and should receive
antibiotic treatment?
To expedite a timely diagnosis of infection var-
ious laboratory markers have been proposed.
Blood levels of C-reactive protein, procalcitonin,
neopterin, etc. are thought to reﬂect closely the
acute-phase protein synthesis stimulated by med-
iators of the local inﬂammatory process [12–15].
Studies have demonstrated that cytokinemia and
elevated levels of procalcitonin and C-reactive
protein correlate with an adverse outcome of infec-
tion [16,17]. On this basis, such measurements
allow the determination risk factors for a compli-
cated course in any febrile patient. Procalcitonin,
the precursor to calcitonin, has been considered by
some to be a speciﬁc and useful indicator of an
invasive infection by bacteria [12–14]. However, in
somewhat different patient groups, other studies
did not conﬁrm the value of procalcitonin mea-
surements to discern between those patients who
are truly infected and those who are not [18–20].
As the acute-phase response is considered to be a
largely nonspeciﬁc reaction to widely different
inﬂammatory stimuli, it is not unexpected that
the procalcitonin or C-reactive protein level is
not exclusively elevated in a host overwhelmed
by invasive, replicating bacteria.
The association between outcome in a patient
with an infection and plasma C-reactive protein,
procalcitonin and cytokine levels could be im-
portant in terms of the reduction in morbidity
and mortality that would follow a successful
identiﬁcation of those patients who might beneﬁt
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from early intervention strategies. In this issue of
Clinical Microbiology and Infection, Dr Brunkhorst
and colleagues examine the relationship between
procalcitonin and changes in the clinical status of
ICU patients with pneumonia [21]. Serial blood
measurements of procalcitonin, C-reactive protein
and other markers were obtained for the ﬁrst 2
weeks after the onset of pneumonia. The authors
found that — besides the compound APACHE II
clinical score — none of the blood measurements
served as an indicator of change in clinical status
or death. It would be interesting to know if the
same conclusion holds when clinical parameters
such as age and severity of underlying disease
are included in the multivariate analysis, and if
a distinction can be made between early deaths
(i.e. due mainly to the acute inﬂammatory
response), and deaths at a later phase of hospital-
ization (i.e. due to co-morbidity and activity of
underlying disease). In this respect, few studies
have compared the yield of measurements of pro-
calcitonin or C-reactive protein relative to clinical
ﬁndings. This issue is of obvious importance to the
practising clinician: what is the use of trying to
identify by laboratory measurements those pa-
tients who are in such a poor condition that they
are easily identiﬁed on clinical grounds alone (e.g.
those in shock), unless of course, such a measure-
ment can help predict who will recover and who
will deteriorate to multiple organ failure. In a
multivariate prediction model of outcome, clinical
data from about 450 patients concerning age,
underlying disease and recent history with respect
to the acute febrile episode were entered, as in a
‘real-life’ encounter between patient and physician
in the acute-care room, followed by endotoxemia,
procalcitonin, TNF-a, IL-6 and IL-10 levels, in due
sequence dictated by the strength of their associa-
tion with outcome [4]. It was found that at best, the
model allowed (at the cost of a 10% false-positive
rate) the identiﬁcation of only about half of
all patients who would have a fatal outcome,
whereas, of all screen-positive patients, less than
one-third dies. Importantly, measuring endotoxin,
procalcitonin, TNF-a, IL-6 and IL-10 levels did not
further enhance clinical judgement alone. Thus,
readily available information, such as age and
activity of underlying disease, as well as the vital
signs, helps the clinician to estimate the severity
of illness. Themodel clearly performs too poorly to
discriminate between those patients who might
beneﬁt from early preventive measures and
those who will not. A fairly high false-positive
rate would be acceptable if the false-negative
rate were very low, but clinicians miss about half
of those who will die because they are screen-
negative and therefore cannot be falsely reassured
about the clinical course in screen-negative
patients. As the study included only patients with
an acute community-acquired febrile illness, it
may have limited power to detect the impact of
predictors of outcome in severely ill patients with
a nosocomial infection and active underlying dis-
ease. The study of Dr Brunkhorst and colleagues in
the present issue extends the information from
previous reports that also in these ICU patients,
measurement of plasma C-reactive protein and
procalcitonin is of limited predictive value for a
diagnosis of clinical deterioration [19,22].
What then should be the role of procalcitonin
and other markers of infection in general clinical
practice? When febrile patients are screened to
identify those with an infection and those at risk
for a complicated course, clinical judgement based
on medical history and physical examination still
outweighs the predictive value of laboratory mar-
kers of infection and the inﬂammatory response. In
evaluating such patients, laboratory tests should
form a logical continuum in conjunction with
medical history and physical examination and
are often most useful when aimed at clarifying
the setting and identifying a possible source of
infection. On the clinical presentation of the
patient, the physician should make his decision
between what amounts to an infectious condition
and what does not, and between what merits
management and what requires close observation.
Future studies should focus on the complex rela-
tionship between plasmamarkers of inﬂammation
and the natural history, especially precursor
stages, of sepsis, severe sepsis and septic shock
in the context of various sources of infection and
underlying disease [23]. Which elevations should
be considered to be physiological variations and
which should be regarded as signiﬁcant and
pathological? Are elevated, pathological measure-
ments always followed by a deterioration of clin-
ical condition? Now that clinical trials with
cytokine-based strategies have proved disappoint-
ing in advanced stages of the systemic inﬂamma-
tory response, such insights will be instrumental in
developing and evaluating treatments that can
either halt or reverse the early stages of the inﬂam-
matory response.
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